Autolus Therapeutics plc reported $117M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $117M (to Q2 2026). Net income: −$280M, trailing twelve months to Q2 2026. Free cash flow: −$235M, trailing twelve months to Q2 2026. Operating margin: −240%, trailing twelve months to Q2 2026.

AUTLAutolus Therapeutics plc

Healthcare

$1.77+18% 1Y

$1.77

$1.2152 weeks$2.54

AUTL as reported

Autolus Therapeutics plc reported $117M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

$117M

Revenue, trailing twelve months · to Q2 2026 · every figure below is as filed, with no scoring applied

Net income: −$280M
Net income · +23% year on year · trailing twelve months to Q2 2026
Free cash flow: −$235M
Free cash flow · −22% year on year · trailing twelve months to Q2 2026
Operating margin: −240%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for AUTL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$117M	n/a	Q2 2026
Net income	−$280M	+23%	Q2 2026
EPS	−$1.06	+26%	Q2 2026
Gross margin	5.5%	n/a	Q2 2026
Operating margin	−240%	n/a	Q2 2026
Net margin	−276%	n/a	Q2 2026
ROE	−221%	n/a	Q2 2026
ROA	−49%	n/a	Q2 2026
Free cash flow	−$235M	−22%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.